A randomized, multi-center, open-label study to compare the safety and efficacy between afatinib monotherapy and combination therapy of afatinib and HAD-B1 for the locally advanced or metastatic NSCLC patients with EGFR mutations: Erratum

doi:10.1097/md.0000000000028585

A randomized, multi-center, open-label study to compare the safety and efficacy between afatinib monotherapy and combination therapy of afatinib and HAD-B1 for the locally advanced or metastatic NSCLC patients with EGFR mutations: Erratum

Medicine ◽

10.1097/md.0000000000028585 ◽

2022 ◽

Vol 101 (2) ◽

pp. e28585

Keyword(s):

Combination Therapy ◽

Locally Advanced ◽

Egfr Mutations ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Safety And Efficacy ◽

Metastatic Nsclc ◽

Nsclc Patients

Download Full-text

A randomized, multi-center, open-label study to compare the safety and efficacy between afatinib monotherapy and combination therapy of afatinib and HAD-B1 for the locally advanced or metastatic NSCLC patients with EGFR mutations

Medicine ◽

10.1097/md.0000000000023455 ◽

2020 ◽

Vol 99 (49) ◽

pp. e23455

Author(s):

Si-Yeon Song ◽

Su-Jeong Ha ◽

Ji-Hye Park ◽

So-Jung Park ◽

Seong Hoon Shin ◽

...

Keyword(s):

Combination Therapy ◽

Locally Advanced ◽

Egfr Mutations ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Safety And Efficacy ◽

Metastatic Nsclc ◽

Nsclc Patients

Download Full-text

19 EGFR mutation rate in TRANSCRIPT: A study to assess the incidence of EGFR mutations in UK NSCLC patients with newly diagnosed locally advanced or metastatic disease. A single arm, open label study

Lung Cancer ◽

10.1016/s0169-5002(14)70020-0 ◽

2014 ◽

Vol 83 ◽

pp. S8

Author(s):

C. Lewanski ◽

I. Hennig ◽

S. Tahir ◽

T. Benepal ◽

S. Skaria ◽

...

Keyword(s):

Mutation Rate ◽

Metastatic Disease ◽

Egfr Mutation ◽

Locally Advanced ◽

Egfr Mutations ◽

Newly Diagnosed ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Nsclc Patients

Download Full-text

An Open-label Study of the Safety and Efficacy of Tag-7 Gene-modified Tumor Cell-based Vaccine in Patients With Locally Advanced or Metastatic Malignant Melanoma or Renal Cell Cancer

Case Medical Research ◽

10.31525/ct1-nct04180774 ◽

2019 ◽

Author(s):

Keyword(s):

Malignant Melanoma ◽

Tumor Cell ◽

Renal Cell ◽

Cell Cancer ◽

Locally Advanced ◽

Metastatic Malignant Melanoma ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Safety And Efficacy

Download Full-text

An open-label study of the safety and efficacy of triple-combination therapy of melasma in african-american patients

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2003.10.478 ◽

2004 ◽

Vol 50 (3) ◽

pp. P138

Author(s):

Pearl E Grimes

Keyword(s):

African American ◽

Combination Therapy ◽

Triple Combination ◽

Open Label ◽

Triple Combination Therapy ◽

Open Label Study ◽

Label Study ◽

Safety And Efficacy

Download Full-text

An open-label study of the safety and efficacy of triple-combination therapy of melasma in African-American patients

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2003.11.028 ◽

2004 ◽

Vol 50 (3) ◽

pp. P176

Author(s):

Pearl Grimes

Keyword(s):

African American ◽

Combination Therapy ◽

Triple Combination ◽

Open Label ◽

Triple Combination Therapy ◽

Open Label Study ◽

Label Study ◽

Safety And Efficacy

Download Full-text

Results from phase II, open-label study of anti-tumoral activity of first-line erlotinib in advanced/metastatic NSCLC patients with EGFR activating mutations, in Portugal: The MuTAR study

Pulmonology ◽

10.1016/j.pulmoe.2020.08.007 ◽

2020 ◽

Author(s):

F. Barata ◽

H. Queiroga ◽

E. Teixeira ◽

T. Almodovar ◽

M. Soares ◽

...

Keyword(s):

Phase Ii ◽

First Line ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Activating Mutations ◽

Metastatic Nsclc ◽

Nsclc Patients

Download Full-text

Abstract OT-03-08: A Phase 2, open-label study to evaluate the safety and efficacy of the probody therapeutic (Pb-Tx) CX-2009 in metastatic HR-Positive/HER2-negative breast cancer (mHR+/HER2− BC) and of CX-2009 as monotherapy and in combination therapy with CX-072 in metastatic triple-negative breast cancer (TNBC)

10.1158/1538-7445.sabcs20-ot-03-08 ◽

2021 ◽

Author(s):

Kathy D. Miller ◽

Leisha A. Emens ◽

Sara Tolaney ◽

Sara A. Hurvitz ◽

Erika Hamilton ◽

...

Keyword(s):

Breast Cancer ◽

Combination Therapy ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Phase 2 ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Safety And Efficacy

Download Full-text

An Open‐Label Study of the Safety and Efficacy of Tag‐7 Gene‐Modified Tumor Cells‐Based Vaccine in Patients with Locally Advanced or Metastatic Malignant Melanoma or Renal Cell Cancer

The Oncologist ◽

10.1634/theoncologist.2020-0160 ◽

2020 ◽

Vol 25 (9) ◽

Author(s):

Aleksei Viktorovich Novik ◽

Anna Borisovna Danilova ◽

Maksim Ivanovich Sluzhev ◽

Tatiana Leonidovna Nehaeva ◽

Sergei Sergeevich Larin ◽

...

Keyword(s):

Malignant Melanoma ◽

Tumor Cells ◽

Renal Cell ◽

Cell Cancer ◽

Locally Advanced ◽

Metastatic Malignant Melanoma ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Safety And Efficacy

Download Full-text

An Open Label Study to Evaluate the Safety and Efficacy of BOR15001L7 for the Treatment of Cold Sores in Patients With Recurrent Herpes Labialis

Case Medical Research ◽

10.31525/ct1-nct03977792 ◽

2019 ◽

Author(s):

Keyword(s):

Herpes Labialis ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Safety And Efficacy ◽

Recurrent Herpes ◽

Cold Sores

Download Full-text

Faculty Opinions recommendation of Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725336183.793540487 ◽

2017 ◽

Author(s):

Lori Ann Birder

Keyword(s):

Overactive Bladder ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Safety And Efficacy ◽

Post Marketing

Download Full-text